Bedaquiline FuMarate

Effects and efficacy:

This product is used as part of combined therapy for the treatment of multidrug-resistant tuberculosis (MDR-TB) in adults and adolescents (12 to <18 years old and weighing ≥30 kg). This product can only be used when no other effective treatment options are available.

Dosage and administration:

The recommended dose for adults and adolescents (12 to <18 years old and weighing ≥30 kg): The recommended dose of this product is 400 mg orally, once a day, for 2 weeks; then 200 mg, 3 times a week, for 22 weeks (at least 48 hours between each dose) (the total duration of treatment is 24 weeks). The same drugs produced by different manufacturers may have inconsistent instructions. The above content is referenced from the instructions for Bedaquiline Fumarate Tablets (National Medicine Standard HJ20171366). If you find inconsistencies in the instructions before taking the drug, please consult a doctor or pharmacist in time.

Adverse reactions:
Serious adverse reactions: death, abnormal heart rhythm and/or hepatitis; other adverse reactions: nausea, joint pain, headache, hemoptysis, chest pain, loss of appetite, rash, increased blood amylase. If serious adverse reactions occur, seek medical attention immediately